Comparative Pharmacology
Head-to-head clinical analysis: ALFENTA versus NORCET.
Head-to-head clinical analysis: ALFENTA versus NORCET.
ALFENTA vs NORCET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
μ-opioid receptor agonist that activates G-protein coupled receptors to inhibit adenylate cyclase, decreasing cAMP production, leading to reduced neuronal excitability and pain transmission.
Combination analgesic: hydrocodone acts as a μ-opioid receptor agonist; acetaminophen inhibits cyclooxygenase (COX) and modulates endocannabinoid system, exerting central analgesic and antipyretic effects.
Intravenous: Initial dose 8-20 mcg/kg (0.5-1 min) then 0.5-3 mcg/kg/min or 3-5 mcg/kg q5-20min. For short procedures: 8-20 mcg/kg. For longer procedures: 50-75 mcg/kg followed by 0.5-3 mcg/kg/min.
1-2 tablets (containing paracetamol 325 mg and tramadol 37.5 mg) orally every 4-6 hours as needed for pain, maximum 8 tablets per day.
None Documented
None Documented
Clinical Note
moderateAlfentanil + Torasemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Torasemide."
Clinical Note
moderateAlfentanil + Etacrynic acid
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Etacrynic acid."
Clinical Note
moderateAlfentanil + Furosemide
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Furosemide."
Clinical Note
moderateAlfentanil + Bumetanide
Terminal elimination half-life: 90–111 minutes (1.5–1.85 hours); prolonged in hepatic impairment.
2-4 hours (terminal); prolonged in hepatic impairment (up to 8-10 hours) and elderly
Primarily renal (urinary) elimination as metabolites; approximately 80% recovered in urine, 20% in feces.
Renal: ~60% unchanged; hepatic metabolism to inactive glucuronide conjugates; biliary/fecal: <5%
Category C
Category C
Opioid Analgesic
Opioid Analgesic
"The risk or severity of adverse effects can be increased when Alfentanil is combined with Bumetanide."